Lung Cancer

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.

Four new and ongoing lung cancer trials are enrolling patients, offering options in first-line and previously treated NSCLC settings.

FDA approved Hernexeos for untreated HER2-mutant NSCLC after 76% of patients had tumor shrinkage in clinical trial data.

Lung Cancer Voices Summit Calls on Congress: Support Research. Save Lives.

Heather Quintana Suchan shares how work and music community support her while she lives fully with stage 4 lung cancer.

This device detects and characterizes lesions on low-dose CT scans, helping patients with cancer get faster, tailored care and avoid unnecessary procedures.

Looking back over the setbacks and blessings of the roller coaster ride that was my cancer treatment journey.

The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing visits.

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control.

Retevmo improved event-free survival in stage 2 to 3A RET fusion-positive non-small cell lung cancer after curative therapy, per phase 3 data.

Heather Quintana Suchan says early biomarker testing at diagnosis helped match her to Rybrevant and urges patients to personalize care and stay active during treatment.

Heather Quintana Suchan, a nonsmoker with stage 4 lung cancer, credits genomic testing and Rybrevant and urges others not to ignore mild symptoms.

A nurse practitioner explains how FDA approval of subcutaneous Rybrevant may reduce treatment burden and improve care for patients with EGFR-mutated lung cancer.

Showing up taking notes and learning the disease can help families feel empowered as new treatments expand hope and quality of life.

Former NFL player and advocate Chris Draft urges patients with cancer to recognize small actions, learn terms and stay engaged to rebuild confidence after diagnosis.

The U.S. FDA has granted Regenerative Medicine Advanced Therapy designation to KB707 for the treatment of advanced/metastatic non-small cell lung cancer.

USC doctors say careful staging and tumor testing help younger patients choose surgery and targeted treatments based on their cancer.

Dr. Joshua Sabari tells CURE that surgery, radiation and systemic therapy can affect the lungs, and he urges exercise and reporting new symptoms early.

Lung carcinoid tumors are rare and often slow growing. Treatment depends on stage and tumor type, with surgery common early and systemic options for advanced disease.

The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after prior targeted treatment.

Small cell lung cancer grows quickly. Learn how it’s diagnosed, staged and treated, and what patients can expect from therapies and side effects.

Patients should understand their cancer, treatment goals and options and record questions to support informed, productive discussions with care teams.

An expert explains how a DLL3 blood test may help guide Imdelltra use and set expectations for patients with small cell lung cancer.

Learn about large cell lung cancer, from diagnosis to stage-specific treatments, side effects and care options to guide patients through their journey.

A U.S. phase 1 trial of Alveltamig opened at UK Markey, where the first patient with small cell lung cancer was treated in late October.